Effect of simvastatin or its combination with ezetimibe on Toll-like receptor expression and lipopolysaccharide - Induced cytokine production in monocytes of hypercholesterolemic patients

Atherosclerosis

Volumn 225, Issue 2, 2012, Pages 381-387

  Moutzouri, Elisavet ^a   Tellis, Constantinos C ^b   Rousouli, Kleopatra ^b   Liberopoulos, Evangelos N ^a   Milionis, Haralambos J ^a   Elisaf, Moses S ^a   Tselepis, Alexandros D ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Ezetimibe; Interleukin 1 ; Interleukin 6; Oxidized LDL; Simvastatin; Toll like receptors

Indexed keywords

CYTOKINE; EZETIMIBE PLUS SIMVASTATIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ADULT; AGED; ARTICLE; BLOOD; CELLULAR DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; INTRACELLULAR MEMBRANE; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MONOTHERAPY; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CYTOKINES; DOWN-REGULATION; DRUG COMBINATIONS; FEMALE; FLOW CYTOMETRY; GREECE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MONOCYTES; PROSPECTIVE STUDIES; SIMVASTATIN; TIME FACTORS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; TREATMENT OUTCOME;

EID: 84869496994     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.08.037     Document Type: Article

References (79)

1. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
2. Yan Z.Q., Hansson G.K. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 2007, 219:187-203.
3. Packard R.R., Lichtman A.H., Libby P. Innate and adaptive immunity in atherosclerosis. Semin Immunopathol 2009, 31:5-22.
4. Medzhitov R., Janeway C.A. Jr., Decoding the patterns of self and nonself by the innate immune system. Science 2002, 296:298-300.
5. Aderem A., Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406:782-787.
6. Liu X., Ukai T., Yumoto H., et al. Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis 2008, 196:146-154.
7. Monaco C., Gregan S.M., Navin T.J., Foxwell B.M., Davies A.H., Feldmann M. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation 2009, 120:2462-2469.
8. Mullick A.E., Soldau K., Kiosses W.B., Bell T.A., Tobias P.S., Curtiss L.K. Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. J Exp Med 2008, 205:373-383.
9. Xu X.H., Shah P.K., Faure E., et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001, 104:3103-3108.
10. Michelsen K.S., Wong M.H., Shah P.K., et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A 2004, 101:10679-10684.
11. Bjorkbacka H., Kunjathoor V.V., Moore K.J., et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004, 10:416-421.
12. Mullick A.E., Tobias P.S., Curtiss L.K. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 2005, 115:3149-3156.
13. Schoneveld A.H., Hoefer I., Sluijter J.P., Laman J.D., de Kleijn D.P., Pasterkamp G. Atherosclerotic lesion development and Toll like receptor 2 and 4 responsiveness. Atherosclerosis 2008, 197:95-104.
14. Geng H.L., Lu H.Q., Zhang L.Z., et al. Increased expression of Toll like receptor 4 on peripheral-blood mononuclear cells in patients with coronary arteriosclerosis disease. Clin Exp Immunol 2006, 143:269-273.
15. Methe H., Kim J.O., Kofler S., Weis M., Nabauer M., Koglin J. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 2005, 111:2654-2661.
16. Kuwahata S., Fujita S., Orihara K., et al. High expression level of Toll-like receptor 2 on monocytes is an important risk factor for arteriosclerotic disease. Atherosclerosis 2010, 209:248-254.
17. Pasini A.F., Anselmi M., Garbin U., et al. Enhanced levels of oxidized low-density lipoprotein prime monocytes to cytokine overproduction via upregulation of CD14 and toll-like receptor 4 in unstable angina. Arterioscler Thromb Vasc Biol 2007, 27:1991-1997.
18. Mizoguchi E., Orihara K., Hamasaki S., et al. Association between Toll-like receptors and the extent and severity of coronary artery disease in patients with stable angina. Coron Artery Dis 2007, 18:31-38.
19. Boekholdt S.M., Agema W.R., Peters R.J., et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 2003, 107:2416-2421.
20. Ameziane N., Beillat T., Verpillat P., et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003, 23:e61-e64.
21. Kiechl S., Lorenz E., Reindl M., et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002, 347:185-192.
22. Labrum R., Bevan S., Sitzer M., Lorenz M., Markus H.S. Toll receptor polymorphisms and carotid artery intima-media thickness. Stroke 2007, 38:1179-1184.
23. Hamann L., Glaeser C., Hamprecht A., Gross M., Gomma A., Schumann R.R. Toll-like receptor (TLR)-9 promotor polymorphisms and atherosclerosis. Clin Chim Acta 2006, 364:303-307.
24. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712-1719.
25. Liao J.K. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005, 96:24F-33F.
26. Alves-Filho J.C., Cunha F.Q. Modulation of toll-like receptor expression: a further effect of statins?. Arterioscler Thromb Vasc Biol 2006, 26:e128.
27. Florentin M., Liberopoulos E.N., Moutzouri E., Rizos C.V., Tselepis A.D., Elisaf M.S. The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin 2011, 27:685-692.
28. Hilgendorff A., Muth H., Parviz B., et al. Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int J Clin Pharmacol Ther 2003, 41:397-401.
29. Ballantyne C.M., Houri J., Notarbartolo A., et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003, 107:2409-2415.
30. Kalogirou M., Tsimihodimos V., Elisaf M. Pleiotropic effects of ezetimibe: do they really exist?. Eur J Pharmacol 2010, 633:62-70.
31. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002, 106:3143-3421.
32. Tsimihodimos V., Karabina S.A., Tambaki A.P., et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol 2002, 22:306-311.
33. Tsouli S.G., Kiortsis D.N., Lourida E.S., et al. Autoantibody titers against OxLDL are correlated with Achilles tendon thickness in patients with familial hypercholesterolemia. J Lipid Res 2006, 47:2208-2214.
34. Ando M., Shibuya A., Tsuchiya K., Akiba T., Nitta K. Reduced expression of Toll-like receptor 4 contributes to impaired cytokine response of monocytes in uremic patients. Kidney Int 2006, 70:358-362.
35. Misumi Y., Miki K., Takatsuki A., Tamura G., Ikehara Y. Novel blockade by brefeldin A of intracellular transport of secretory proteins in cultured rat hepatocytes. J Biol Chem 1986, 261:11398-11403.
36. Billack B. Macrophage activation: role of toll-like receptors, nitric oxide, and nuclear factor kappa B. Am J Pharm Educ 2006, 70:102.
37. Miller Y.I. Toll-like receptors and atherosclerosis: oxidized LDL as an endogenous Toll-like receptor ligand. Future Cardiol 2005, 1:785-792.
38. Miller Y.I., Viriyakosol S., Binder C.J., Feramisco J.R., Kirkland T.N., Witztum J.L. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 2003, 278:1561-1568.
39. Miller Y.I., Viriyakosol S., Worrall D.S., Boullier A., Butler S., Witztum J.L. Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler Thromb Vasc Biol 2005, 25:1213-1219.
40. Chavez-Sanchez L, Madrid-Miller A, Chavez-Rueda K, Legorreta-Haquet MV, Tesoro-Cruz E, Blanco-Favela F. Activation of TLR2 and TLR4 by minimally modified low-density lipoprotein in human macrophages and monocytes triggers the inflammatory response. Hum Immunol. 71: 737-44.
41. Ghanim H., Mohanty P., Deopurkar R., et al. Acute modulation of toll-like receptors by insulin. Diabetes Care 2008, 31:1827-1831.
42. Dasu M.R., Devaraj S., Park S., Jialal I. Increased toll-like receptor activation and TLR ligands in recently diagnosed type 2 diabetes subjects. Diabetes Care 2010, 33:861-868.
43. Dasu M.R., Devaraj S., Zhao L., Hwang D.H., Jialal I. High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes 2008, 57:3090-3098.
44. Devaraj S., Dasu M.R., Park S.H., Jialal I. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia 2009, 52:1665-1668.
45. Ghanim H., Abuaysheh S., Sia C.L., et al. Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care 2009, 32:2281-2287.
46. Deopurkar R., Ghanim H., Friedman J., et al. Differential effects of cream, glucose, and orange juice on inflammation, endotoxin, and the expression of Toll-like receptor-4 and suppressor of cytokine signaling-3. Diabetes Care 2010, 33:991-997.
47. Hodgkinson C.P., Ye S. Statins inhibit toll-like receptor 4-mediated lipopolysaccharide signaling and cytokine expression. Pharmacogenet Genom 2008, 18:803-813.
48. Chansrichavala P., Chantharaksri U., Sritara P., Chaiyaroj S.C. Atorvastatin attenuates TLR4-mediated NF-kappaB activation in a MyD88-dependent pathway. Asian Pac J Allergy Immunol 2009, 27:49-57.
49. Methe H., Kim J.O., Kofler S., Nabauer M., Weis M. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol 2005, 25:1439-1445.
50. Wang Y., Zhang M.X., Meng X., et al. Atorvastatin suppresses LPS-induced rapid upregulation of Toll-like receptor 4 and its signaling pathway in endothelial cells. Am J Physiol Heart Circ Physiol 2011, 300:H1743-H1752.
51. Teusch N., Lombardo E., Eddleston J., Knaus U.G. The low molecular weight GTPase RhoA and atypical protein kinase Czeta are required for TLR2-mediated gene transcription. J Immunol 2004, 173:507-514.
52. Oda K., Kitano H. A comprehensive map of the toll-like receptor signaling network. Mol Syst Biol 2006, 2:0015.
53. Curtiss L.K., Tobias P.S. The toll of Toll-like receptors, especially toll-like receptor 2, on murine atherosclerosis. Curr Drug Targets 2007, 8:1230-1238.
54. Lin H., Xiao Y., Chen G., et al. HMG-CoA reductase inhibitor simvastatin suppresses Toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in monocytes from rheumatoid arthritis patients. Rheumatol Int 2011, 31:1451-1458.
55. Niessner A., Steiner S., Speidl W.S., et al. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 2006, 189:408-413.
56. Guyton J.R., Betteridge D.J., Farnier M., et al. Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes. Diab Vasc Dis Res 2011, 8:160-172.
57. Pesaro A.E., Serrano C.V., Fernandes J.L., et al. Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. Int J Cardiol 2012, 158:400-404.
58. Undas A., Machnik A., Potaczek D.P., Wypasek E., Zmudka K., Tracz W. Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events. J Cardiovasc Pharmacol 2011, 58:167-172.
59. Krysiak R., Zmuda W., Okopien B. The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels. J Intern Med 2012, 271:32-42.
60. Araujo D.B., Bertolami M.C., Ferreira W.P., et al. Pleiotropic effects with equivalent low-density lipoprotein cholesterol reduction: comparative study between simvastatin and simvastatin/ezetimibe coadministration. J Cardiovasc Pharmacol 2010, 55:1-5.
61. Kostapanos M.S., Spyrou A.T., Tellis C.C., et al. Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress. Lipids 2011, 46:341-348.
62. Saougos V.G., Tambaki A.P., Kalogirou M., et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007, 27:2236-2243.
63. Lee S.H., Kang S.M., Park S., Jang Y., Chung N., Choi D. The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A. Clin Cardiol 2011, 34:108-112.
64. Nakou E.S., Filippatos T.D., Kiortsis D.N., et al. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother 2008, 9:3151-3158.
65. Guha M., Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001, 13:85-94.
66. Medzhitov R., Preston-Hurlburt P., Janeway C.A. A human homologue of the drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388:394-397.
67. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
68. Schnare M., Barton G.M., Holt A.C., Takeda K., Akira S., Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001, 2:947-950.
69. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006, 86:515-581.
70. Erridge C., Spickett C.M. Oxidised phospholipid regulation of Toll-like receptor signalling. Redox Rep 2007, 12:76-80.
71. Tsimikas S. Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease. Am J Cardiol 2006, 98:9P-17P.
72. Leitinger N. Oxidized phospholipids as triggers of inflammation in atherosclerosis. Mol Nutr Food Res 2005, 49:1063-1071.
73. Erridge C., Kennedy S., Spickett C.M., Webb D.J. Oxidized phospholipid inhibition of toll-like receptor (TLR) signaling is restricted to TLR2 and TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition. J Biol Chem 2008, 283:24748-24759.
74. Walton K.A., Cole A.L., Yeh M., et al. Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2. Arterioscler Thromb Vasc Biol 2003, 23:1197-1203.
75. Marson A., Lawn R.M., Mikita T. Oxidized low density lipoprotein blocks lipopolysaccharide-induced interferon beta synthesis in human macrophages by interfering with IRF3 activation. J Biol Chem 2004, 279:28781-28788.
76. Oskolkova O.V., Afonyushkin T., Preinerstorfer B., et al. Oxidized phospholipids are more potent antagonists of lipopolysaccharide than inducers of inflammation. J Immunol 2010, 185:7706-7712.
77. Diomede L., Albani D., Sottocorno M., et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001, 21:1327-1332.
78. Krysiak R., Okopien B. The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia. J Cardiovasc Pharmacol 2011, 57:505-512.
79. Nochioka K., Tanaka S.I., Miura M., et al. Ezetimibe improves endothelial function and inhibits Rho-kinase activity associated with inhibition of cholesterol absorption in humans. Circ J 2012 Apr 28, [Epub ahead of print].